Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03005782
Title Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Age Groups: senior | adult
Covered Countries USA | GBR | AUS

No variant requirements are available.